MB076 is an innovative heterocyclic triazole designed with enhanced plasma stability. It effectively inhibits seven distinct Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with K i values less than 1 μM. Additionally, MB076 demonstrates a synergistic effect when combined with various cephalosporins to restore pBCSK(−) susceptibility [1].

MB076 (compound B) demonstrates exceptional stability in human plasma at concentrations ranging from 0.5 to 5 μM over 48 hours, with a half-life (t1/2) of 29 hours, significantly exceeding the 9 hours observed for ADC-7/S02030 (PDB4U0X) [1]. Additionally, when combined at a concentration of 10 μg/mL with Ceftazidime (CAZ) and Cefotaxime (CTX) for 48 hours, MB076 synergistically restores drug sensitivity in pBCSK(-) [1]. Cell viability assays [1] conducted in human plasma with concentrations from 0.5 μM to 5 μM and an incubation period of 48 hours further confirm the compound’s outstanding stability.